About the Company
We do not have any company description for Inhibrx Biosciences, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc.: Inhibrx Reports Second Quarter 2025 Financial Results
Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the second quarter ...
Inhibrx Biosciences Announces Departure of CSO and ... - Morningstar
Inhibrx Biosciences was incorporated in January 2024 as a direct, wholly-owned subsidiary of Inhibrx, Inc. Prior to the sale of Inhibrx, Inc. and the INBRX-101 program to Sanofi S.A., Inhibrx ...
Inhibrx Biosciences Announces Loan Agreement with Oxford Finance
SAN DIEGO, Jan. 13, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (INBX) ("Inhibrx" or the "Company"), a biopharmaceutical company with two programs in ongoing clinical trials, today announced it ...
Inhibrx Biosciences Announces Departure of CSO and Appointments of New ...
Inhibrx Biosciences was incorporated in January 2024 as a direct, wholly-owned subsidiary of Inhibrx, Inc. Prior to the sale of Inhibrx, Inc. and the INBRX-101 program to Sanofi S.A., Inhibrx ...
INBX - Inhibrx Biosciences Inc Key Metrics | Morningstar
Review the current Inhibrx Biosciences Inc (INBX:XNAS) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if INBX is the best investment for you.
Inhibrx Biosciences Reports Third Quarter 2024 Financial Results
--Inhibrx Biosciences, Inc. today reported financial results for the third quarter of 2024. Following the completion of the sale of INBRX-101 by Inhibrx, Inc. to Sanofi S.A. and the Former Parent ...
Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results
SAN DIEGO, March 17, 2025 /PRNewswire/ — Inhibrx Biosciences, Inc. (Nasdaq: INBX) (“Inhibrx” or the “Company”) today reported financial results for the fourth quarter and fiscal year 2024.
Inhibrx Biosciences Inc. Stock Grades | INBX | Barron's
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering ...
Inhibrx, Inc. Announces Record Date and Expected Distribution Time for ...
SAN DIEGO, May 8, 2024 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx," or the "Company") today announced that it has set a record date of May 17, 2024 (the "Record Date") for the ...
Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial ...
Inhibrx Biosciences was incorporated in January 2024 as a direct, wholly-owned subsidiary of Inhibrx, Inc. Prior to the sale of Inhibrx, Inc. and the INBRX-101 program to Sanofi S.A., Inhibrx ...
Similar Companies
Loading the latest forecasts...